Pharmaceutical

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).

Jul 18, 2024 - 04:00
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
China’s NMPA has granted approval for Zai Lab and argenx's efgartigimod SC for the treatment of generalised myasthenia gravis (gMG).
Read the original article

Tags:

Previous Article

Scorpion Therapeutics secures $150m for oncology pipeline

Next Article

FDA issues CRL to Orexo’s NDA for opioid overdose medication

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy

Verona scores FDA approval for Ohtuvayre as COPD mainte...

Jun 28, 2024

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan...

Oct 20, 2024

STAT+: Vaccines save lives and generate profits. Why is investment lagging?

STAT+: Vaccines save lives and generate profits. Why is...

Jan 26, 2024